SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations
The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD)...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Nephrology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2024.1332397/full |
| _version_ | 1827160172590530560 |
|---|---|
| author | Erietta Polychronopoulou Erietta Polychronopoulou Fanny Bourdon Daniel Teta |
| author_facet | Erietta Polychronopoulou Erietta Polychronopoulou Fanny Bourdon Daniel Teta |
| author_sort | Erietta Polychronopoulou |
| collection | DOAJ |
| description | The beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD). In addition, a recent meta-analysis of 13 large led by the ‘SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium’ (SMART-C) provided solid evidence of SGLT2i beneficial effects in CKD or in patients with heart failure, with and without diabetes. Collectively, the patients treated with SGLT2i had a decreased risk of CKD progression, acute kidney injury (AKI), end-stage kidney disease (ESKD) or death from heart failure. Whether these cardio-renal benefits should be extrapolated to kidney transplant recipients (KTR) needs to be assessed in further studies. In this article, we report recent data accumulated so far in the literature, looking at the efficacy and safety of SGLT2i in diabetic and non-diabetic KTR. We found encouraging data regarding the use of SGLT2i in KTR with diabetes. These agents appeared to be safe, and they reduced body weight and blood pressure in this group of patients. Potential effects on kidney graft function and survival are yet to be investigated. |
| first_indexed | 2024-04-24T09:44:02Z |
| format | Article |
| id | doaj.art-1a10681a17df40abaf6f5edfae44b67b |
| institution | Directory Open Access Journal |
| issn | 2813-0626 |
| language | English |
| last_indexed | 2025-03-21T00:08:48Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nephrology |
| spelling | doaj.art-1a10681a17df40abaf6f5edfae44b67b2024-08-03T09:57:10ZengFrontiers Media S.A.Frontiers in Nephrology2813-06262024-04-01410.3389/fneph.2024.13323971332397SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectationsErietta Polychronopoulou0Erietta Polychronopoulou1Fanny Bourdon2Daniel Teta3Service of Nephrology, Hôpital du Valais, Sion, SwitzerlandTransplantation Center, Lausanne University Hospital and University of Lausanne, Lausanne, SwitzerlandService of Nephrology, Hôpital du Valais, Sion, SwitzerlandService of Nephrology, Hôpital du Valais, Sion, SwitzerlandThe beneficial effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown recently in numerous randomized controlled trials (RCT) and systematic reviews. According to KDIGO guidelines, SGLT2i currently represent a first choice for diabetic patients with chronic kidney disease (CKD). In addition, a recent meta-analysis of 13 large led by the ‘SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium’ (SMART-C) provided solid evidence of SGLT2i beneficial effects in CKD or in patients with heart failure, with and without diabetes. Collectively, the patients treated with SGLT2i had a decreased risk of CKD progression, acute kidney injury (AKI), end-stage kidney disease (ESKD) or death from heart failure. Whether these cardio-renal benefits should be extrapolated to kidney transplant recipients (KTR) needs to be assessed in further studies. In this article, we report recent data accumulated so far in the literature, looking at the efficacy and safety of SGLT2i in diabetic and non-diabetic KTR. We found encouraging data regarding the use of SGLT2i in KTR with diabetes. These agents appeared to be safe, and they reduced body weight and blood pressure in this group of patients. Potential effects on kidney graft function and survival are yet to be investigated.https://www.frontiersin.org/articles/10.3389/fneph.2024.1332397/fullSGLT2 inhibitorkidney transplantationdiabetic kidney diseasepost transplantation diabetes mellitusdiabetic kidney transplant recipientsCKD - chronic kidney disease |
| spellingShingle | Erietta Polychronopoulou Erietta Polychronopoulou Fanny Bourdon Daniel Teta SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations Frontiers in Nephrology SGLT2 inhibitor kidney transplantation diabetic kidney disease post transplantation diabetes mellitus diabetic kidney transplant recipients CKD - chronic kidney disease |
| title | SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations |
| title_full | SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations |
| title_fullStr | SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations |
| title_full_unstemmed | SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations |
| title_short | SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations |
| title_sort | sglt2 inhibitors in diabetic and non diabetic kidney transplant recipients current knowledge and expectations |
| topic | SGLT2 inhibitor kidney transplantation diabetic kidney disease post transplantation diabetes mellitus diabetic kidney transplant recipients CKD - chronic kidney disease |
| url | https://www.frontiersin.org/articles/10.3389/fneph.2024.1332397/full |
| work_keys_str_mv | AT eriettapolychronopoulou sglt2inhibitorsindiabeticandnondiabetickidneytransplantrecipientscurrentknowledgeandexpectations AT eriettapolychronopoulou sglt2inhibitorsindiabeticandnondiabetickidneytransplantrecipientscurrentknowledgeandexpectations AT fannybourdon sglt2inhibitorsindiabeticandnondiabetickidneytransplantrecipientscurrentknowledgeandexpectations AT danielteta sglt2inhibitorsindiabeticandnondiabetickidneytransplantrecipientscurrentknowledgeandexpectations |